as 11-21-2024 4:00pm EST
Neurogene Inc is a clinical stage biotechnology company whose objective is to harness the power of gene therapy which is combined with its EXACT gene regulation technology to turn today's complex devastating neurological diseases into treatable conditions.
Founded: | 2003 | Country: | United States |
Employees: | N/A | City: | NEW YORK |
Market Cap: | 471.1M | IPO Year: | N/A |
Target Price: | $60.80 | AVG Volume (30 days): | 539.5K |
Analyst Decision: | Strong Buy | Number of Analysts: | 6 |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | -0.26 | EPS Growth: | N/A |
52 Week Low/High: | $12.49 - $74.49 | Next Earning Date: | 11-18-2024 |
Revenue: | $925,000 | Revenue Growth: | N/A |
Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
NGNE Breaking Stock News: Dive into NGNE Ticker-Specific Updates for Smart Investing
Business Wire
3 days ago
Investor's Business Daily
3 days ago
Business Wire
3 days ago
Investor's Business Daily
9 days ago
GuruFocus.com
9 days ago
Business Wire
10 days ago
TipRanks
16 days ago
Business Wire
17 days ago
The information presented on this page, "NGNE Neurogene Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.